| 2.12 -0.02 (-0.93%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.72  |
1-year : | 4.66 |
| Resists | First : | 3.19 |
Second : | 3.99 |
| Pivot price | 2.47 |
|||
| Supports | First : | 1.89 |
Second : | 1.58 |
| MAs | MA(5) : | 2.18 |
MA(20) : | 2.62 |
| MA(100) : | 2.93 |
MA(250) : | 3.7 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 13 |
| RSI | RSI(14): 28.3 |
|||
| 52-week | High : | 7.42 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALRN ] has closed above bottom band by 14.8%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.26 - 2.27 | 2.27 - 2.28 |
| Low: | 1.87 - 1.88 | 1.88 - 1.89 |
| Close: | 2.09 - 2.12 | 2.12 - 2.14 |
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Sat, 30 Nov 2024
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat
Thu, 14 Nov 2024
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
Thu, 14 Nov 2024
Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan
Thu, 14 Nov 2024
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PR Newswire
Wed, 13 Nov 2024
Aileron's IPF Drug Shows Promising Results: 7 of 8 Biomarkers Improve in Phase 1b Trial | ALRN Stock News - StockTitan
Wed, 13 Nov 2024
Aileron reports promising phase 1b trial results for IPF treatment - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 28.4 (%) |
| Shares Short | 233 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -2.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.74 |
| PEG Ratio | 0 |
| Price to Book value | 1.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|